focus -WSS

focus

author：comprehensive 2025-09-28 23:11:32 - browse：847

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Medicare Advantage 2025 payments will dip, Biden administration says

WSS

A new crop of companies is reshaping the health data economy

Hundreds died while taking an arthritis drug, but nobody alerted patients

Device maker Teleflex to acquire urology company for $600M

U.K. decision on ALS drug has neurologists, advocates up in arms

Hundreds died while taking an arthritis drug, but nobody alerted patients

The haunting brain science of long Covid

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

Study: Black kids more likely to die after surgery than white kids

New air purifier tech could be key to improving indoor air quality

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

As demand for Covid shots wanes, Moderna seeks its next success

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Activists slam private health insurers over coverage restrictions

Covid silver lining: Unprecedented look at human immune system

As demand for Covid shots wanes, Moderna seeks its next success

First Opinion on colorectal cancer screening: letter and response

leisure time

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Gut bacteria may contribute to kidney autoimmunity, study finds

UnitedHealth, in a surprise, takes aim at Steward’s physician group

Scientists uncover potential path to treating deadly childhood tumor

Why patients can’t get everything they want on drug pricing

Senate panel puts off hardest PBM reforms for another day

Wikipedia

leisure time

Wikipedia

focus